Latest news with #RituBaral
Business Insider
19 hours ago
- Business
- Business Insider
TD Cowen Remains a Hold on Spero Therapeutics (SPRO)
TD Cowen analyst Ritu Baral maintained a Hold rating on Spero Therapeutics (SPRO – Research Report) today. The company's shares closed today at $2.85. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Baral covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Vera Therapeutics. According to TipRanks, Baral has an average return of 7.1% and a 47.08% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for Spero Therapeutics.
Business Insider
19-05-2025
- Business
- Business Insider
TD Cowen Reaffirms Their Hold Rating on Spero Therapeutics (SPRO)
TD Cowen analyst Ritu Baral maintained a Hold rating on Spero Therapeutics (SPRO – Research Report) yesterday. The company's shares closed last Friday at $0.65. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Baral is a 3-star analyst with an average return of 2.5% and a 39.31% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Alnylam Pharma, and Madrigal Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Spero Therapeutics. SPRO market cap is currently $36.4M and has a P/E ratio of -0.51.
Business Insider
19-05-2025
- Business
- Business Insider
TD Cowen Sticks to Their Hold Rating for Milestone Pharmaceuticals (MIST)
TD Cowen analyst Ritu Baral maintained a Hold rating on Milestone Pharmaceuticals (MIST – Research Report) yesterday. The company's shares closed last Friday at $1.22. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Baral is a 3-star analyst with an average return of 2.5% and a 39.31% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Alnylam Pharma, and Madrigal Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Milestone Pharmaceuticals with a $7.50 average price target. MIST market cap is currently $65.23M and has a P/E ratio of -1.47.
